Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ability of Intranasal Transmucosal Fentanyl Pectin Nasal Spray to Prevent Breakthrough Pain Episodes in Patients With Radiation-induced Oropharyngeal Mucositis

NCT02050503 is registered in ClinicalTrials.gov with Grupo de Investigación Clínica en Oncología Radioterapia as lead sponsor.

NCT NCT02050503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02050503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ability of Intranasal Transmucosal Fentanyl Pectin Nasal Spray to Prevent Breakthrough Pain Episodes in Patients With Radiation-induced Oropharyngeal Mucositis
Lead sponsor
Grupo de Investigación Clínica en Oncología Radioterapia
Phase
Observational
Overall status
Completed
Start date
December 31, 2012
Completion date
June 30, 2014
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breakthrough pain, chemotherapy, head and neck cancer, mucositis, radiotherapy